What is a reasonable dose of olmesartan (Angiotensin II Receptor Blocker) to start a patient on when converting from lisinopril (Angiotensin-Converting Enzyme Inhibitor) 40mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting Lisinopril 40mg to Olmesartan

Start olmesartan at 20 mg once daily when converting from lisinopril 40 mg daily, then titrate to 40 mg once daily after 2 weeks if blood pressure control is inadequate. 1, 2

Rationale for Starting Dose

  • Lisinopril 40 mg represents the maximum recommended daily dose for hypertension, placing the patient at the upper end of ACE inhibitor therapy 1
  • Olmesartan 20 mg once daily is the recommended starting dose for most patients according to FDA labeling and ACC/AHA guidelines 1, 2
  • The olmesartan dose range is 20-40 mg daily, with 40 mg being the maximum approved dose that provides optimal blood pressure reduction 1, 2

Titration Strategy

  • After 2 weeks on olmesartan 20 mg daily, increase to 40 mg once daily if blood pressure remains uncontrolled (≥130/80 mmHg for most adults) 2, 3
  • Olmesartan demonstrates dose-dependent efficacy, with the 40 mg dose producing significantly greater blood pressure reductions (approximately 12/7 mmHg from baseline) compared to 20 mg (approximately 10/6 mmHg) 2, 4
  • Doses above 40 mg do not provide additional benefit, and twice-daily dosing offers no advantage over once-daily administration 2

Clinical Considerations During Conversion

  • Monitor blood pressure within 1-2 weeks after switching to assess adequacy of initial olmesartan dose 5
  • Check serum creatinine and potassium within 1-2 weeks after conversion, as both ACE inhibitors and ARBs carry risk of hyperkalemia and renal dysfunction 1, 5
  • Ensure adequate washout if patient has history of angioedema with ACE inhibitors - wait at least 6 weeks after discontinuing lisinopril before starting olmesartan 1
  • Consider starting at a lower dose (10-20 mg) in volume-depleted patients or those on concurrent diuretic therapy 2

Expected Outcomes

  • Onset of antihypertensive effect occurs within 1 week, with maximal effect by 2 weeks 2, 6
  • At 40 mg daily, olmesartan provides 24-hour blood pressure control with trough-to-peak ratios of 60-80% 2
  • Olmesartan 40 mg has demonstrated superior or equivalent efficacy compared to other ARBs and ACE inhibitors in comparative trials 6, 7

Common Pitfalls to Avoid

  • Never combine olmesartan with ACE inhibitors - this increases risk of hyperkalemia, syncope, and acute kidney injury without additional benefit 1, 5
  • Do not start at 40 mg in most patients - the FDA-approved starting dose is 20 mg, with titration based on response 2
  • Avoid abrupt discontinuation of lisinopril - transition directly to olmesartan on the same day to maintain continuous renin-angiotensin system blockade 1
  • Do not exceed 40 mg daily of olmesartan - higher doses provide no additional efficacy 2

If Blood Pressure Remains Uncontrolled on Olmesartan 40mg

  • Add hydrochlorothiazide 12.5-25 mg daily rather than exceeding the maximum olmesartan dose 1, 3
  • Combination therapy with olmesartan 20 mg plus hydrochlorothiazide 12.5 mg has been shown to be more effective than olmesartan 40 mg monotherapy in non-responders 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007

Guideline

Optimal Dosing of Losartan for Hypertension and Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.